Special Issue

Gene- and Peptide-Based Therapeutics for Neurodegenerative Disorders

Message from the Guest Editors

Recent advances in gene- and peptide-based therapeutics are transforming the treatment landscape by offering precision-targeted interventions to modulate disease pathways, restore cellular homeostasis, and improve neuroprotection. This Special Issue invites cutting-edge research and reviews exploring novel genetic and peptide-based approaches, including gene editing, RNA-based strategies, peptide mimetics, and targeted delivery systems. We welcome contributions that highlight translational potential, mechanistic insights, and innovative preclinical or clinical developments in the field. By bringing together the latest advancements, we aim to foster the development of new strategies to address neurodegeneration and accelerate the path toward effective treatments. As a joint Special Issue

between *Pharmaceutics* and *Biomedicines*, we invite both pharmaceutical studies on drug delivery, nanoparticle-based carriers, polymeric systems, and targeted delivery strategies and biomedical studies focusing on therapeutic mechanisms, biomarker identification, neuroinflammation, and diseasemodifying strategies.

Guest Editors

Dr. Ramona Meanti

Department of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy

Dr. Chiara Lucchi

Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41100 Modena, Italy

Deadline for manuscript submissions

31 December 2025



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/236772

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

